134 related articles for article (PubMed ID: 37229975)
21. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
22. Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.
Oliveira LM; Falomir-Lockhart LJ; Botelho MG; Lin KH; Wales P; Koch JC; Gerhardt E; Taschenberger H; Outeiro TF; Lingor P; Schüle B; Arndt-Jovin DJ; Jovin TM
Cell Death Dis; 2015 Nov; 6(11):e1994. PubMed ID: 26610207
[TBL] [Abstract][Full Text] [Related]
23. Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease.
Akrioti E; Karamitros T; Gkaravelas P; Kouroupi G; Matsas R; Taoufik E
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883433
[TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
25. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.
Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T
Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007
[TBL] [Abstract][Full Text] [Related]
26. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
[TBL] [Abstract][Full Text] [Related]
27. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication.
Ishikawa KI; Shiga T; Yoshino H; Nishioka K; Hattori N; Akamatsu W
Stem Cell Res; 2024 Feb; 74():103296. PubMed ID: 38154385
[TBL] [Abstract][Full Text] [Related]
28. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of SNCA gene expression: implications to synucleinopathies.
Tagliafierro L; Chiba-Falek O
Neurogenetics; 2016 Jul; 17(3):145-57. PubMed ID: 26948950
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.
Kantor B; Tagliafierro L; Gu J; Zamora ME; Ilich E; Grenier C; Huang ZY; Murphy S; Chiba-Falek O
Mol Ther; 2018 Nov; 26(11):2638-2649. PubMed ID: 30266652
[TBL] [Abstract][Full Text] [Related]
31. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription.
Ryan SD; Dolatabadi N; Chan SF; Zhang X; Akhtar MW; Parker J; Soldner F; Sunico CR; Nagar S; Talantova M; Lee B; Lopez K; Nutter A; Shan B; Molokanova E; Zhang Y; Han X; Nakamura T; Masliah E; Yates JR; Nakanishi N; Andreyev AY; Okamoto S; Jaenisch R; Ambasudhan R; Lipton SA
Cell; 2013 Dec; 155(6):1351-64. PubMed ID: 24290359
[TBL] [Abstract][Full Text] [Related]
32. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
[TBL] [Abstract][Full Text] [Related]
33. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
34. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease.
Guhathakurta S; Kim J; Adams L; Basu S; Song MK; Adler E; Je G; Fiadeiro MB; Kim YS
EMBO Mol Med; 2021 Feb; 13(2):e12188. PubMed ID: 33428332
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
36. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
37. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
[TBL] [Abstract][Full Text] [Related]
38. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
39. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Markopoulou K; Dickson DW; McComb RD; Wszolek ZK; Katechalidou L; Avery L; Stansbury MS; Chase BA
Acta Neuropathol; 2008 Jul; 116(1):25-35. PubMed ID: 18389263
[TBL] [Abstract][Full Text] [Related]
40. Generation of patient-derived pluripotent stem cell-lines and CRISPR modified isogenic controls with mutations in the Parkinson's associated GBA gene.
X-Q Chen C; Deneault E; Abdian N; You Z; Sirois J; Nicouleau M; Shlaifer I; Villegas L; Boivin MN; Gaborieau L; Karamchandani J; Beitel LK; Fon EA; Durcan TM
Stem Cell Res; 2022 Oct; 64():102919. PubMed ID: 36130446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
